Synta Pharmaceuticals Company Description
Synta isn't a foreign roly-poly elf who brings gifts to tots in the wintertime, but it might be able to bring healthier times to those suffering from illness. Synta Pharmaceuticals develops drugs for immune and metabolic disorders and cancer. The company's clinical-stage drugs include Elesclomol (formerly STA-4783) for cancerous tumor treatment, Apilimod (or STA-5326) for the treatment for rheumatoid arthritis and other inflammatory diseases, and STA-9090 (an Hsp90 inhibitor) for cancer. Synta's pre-clinical developments include ion channel modulators for autoimmune diseases and vascular disrupting agents for cancer.
View the Comprehensive Company Description for Synta Pharmaceuticals
The Company Description provides a historical perspective of Synta Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Synta Pharmaceuticals's evolution in the marketplace.
